“The revolutionary technology behind DotLab’s endometriosis test could improve the lives of the hundreds of millions of women affected by this debilitating disease which has been under-researched and deprioritized for too long,” Heather Bowerman, CEO of DotLab, a healthcare technology company focused on personalized medicine for women’s health, said in a press release.
The financing was led by CooperSurgical, one of the two business units of The Cooper Companies, with individual investors from Tiger Global Management and Luxor Capital Group, as well as from the law firm Wilson Sonsini Goodrich & Rosati.
“CooperSurgical brings significant operational resources and the opportunity to build upon partnerships with health systems to become a leading brand in women’s health,” Bowerman said. “Our shared goal is to make DotLab’s endometriosis test widely accessible.”
The current diagnostic test for endometriosis is laparoscopy, an invasive surgical procedure in which a surgeon inserts a laparoscope (a small fiber-optic viewing device similar to a telescope) into a patient’s abdominal cavity to look for lesions caused by endometriosis.
Laparoscopic surgery may also be used as a form of treatment to remove endometrial lesions and cysts.
In an effort to develop a noninvasive and accurate diagnostic test for endometriosis, DotLab has been working on a test that combines information from a set of new disease biomarkers with machine learning algorithms. The result is its proprietary DotEndo test.
Last year, the company started collaborating with investigators from Yale University to evaluate the performance of DotEndo, compared with standard laparoscopic surgery, in identifying endometriosis in a group of women with and without the disorder.
“DotLab plans to use its Series A financing to further clinical validation, expand market access, and continue to grow our team in the pursuit of our goals,” Bowerman said.